Capital Fund Management S.A. Prothena Corp Public LTD CO Transaction History

Capital Fund Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $1.55 Million - $1.94 Million	29,772 New	29,772 $1.79 Million
Q2 2022 Aug 12, 2022	BUY	$22.73 - $39.98 $388,751 - $683,777	17,103 Added 14.21%	137,496 $3.73 Million
Q1 2022 May 12, 2022	BUY	$30.27 - $49.22 $2.07 Million - $3.36 Million	68,330 Added 131.24%	120,393 $4.4 Million
Q4 2021 Feb 10, 2022	BUY	$42.11 - $73.26 $2.19 Million - $3.81 Million	52,063 New	52,063 $2.57 Million
Q4 2019 Feb 13, 2020	SELL	$7.48 - $17.01 $351,560 - $799,470	-47,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$6.89 - $10.45 $10,335 - $15,674	1,500 Added 3.3%	47,000 $368,000
Q2 2019 Aug 12, 2019	BUY	$8.85 - $12.49 $402,675 - $568,295	45,500 New	45,500 $481,000
Q1 2018 May 15, 2018	SELL	$27.95 - $45.04 $245,960 - $396,352	-8,800 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$35.44 - $63.76 $311,872 - $561,088	8,800	8,800 $330,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.